AlphaMeld Corporation
Govindan Vijayadamodar is a seasoned professional in the field of AI applications and informatics, currently serving as Vice President of AI Applications at AlphaMeld Corporation since January 2025 and at InveniAI LLC since April 2017. Vijayadamodar has an extensive background, having previously held the position of Director of Informatics at BioXcel Corporation from March 2011 to March 2025, and Senior Informatics Analyst at Clinical Data from January 2010 to January 2011. Early career highlights include serving as Project Leader at both 454 Life Sciences (Roche Diagnostics) and curagen corporation from October 2004 to 2009 and August 1997 to October 2004, respectively. Academically, Vijayadamodar holds a Ph.D. in Chemical Physics/Physical Chemistry from the Indian Institute of Science (IISc) and an M.B.A. from the University of New Haven.
This person is not in any offices
AlphaMeld Corporation
Headquartered in Guilford, CT, AlphaMeld® Corporation (a wholly owned subsidiary of InveniAI LLC) stands as a global frontrunner in the application of AI, machine learning, and generative AI tools, catalyzing innovation throughout drug discovery and development. With a mission to identify and expedite transformative therapies for diseases with unmet medical needs, the company utilizes its cutting-edge AlphaMeld platform to extract valuable insights from petabytes of diverse data sets, propelling the creation of groundbreaking drug programs. The company's pioneering approach is underscored by successful collaborations with industry leaders and drug spinouts, solidifying its position as a trailblazer in the realm of AI-driven drug discovery. About The AlphaMeld® Platform The AlphaMeld platform employs a comprehensive approach to generate testable hypotheses, considering factors such as the ideal mode of pharmacotherapy, disease severity, gene ontology, disease pathways, proteinopathies, standard of care, emerging innovation, and enabling technologies. This is done while factoring in medical, scientific, strategic, and commercial considerations.